June 14, 2023 12:24 PM EDTUpdated 03:40 PM

Viatris petitions FDA over would-be EpiPen competitor, claiming more data necessary

Zachary Brennan

Senior Editor

Viatris, over the last two years, pulled in more than $750 million from its EpiPen autoinjector, a key emergency treatment for anaphylaxis. So it should …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Viatris petitions FDA over would-be EpiPen competitor, claiming more data necessary

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Vi­a­tris pe­ti­tions FDA over would-be EpiPen com­peti­tor, claim­ing more da­ta nec­es­sary

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Viatris petitions FDA over would-be EpiPen competitor, claiming more data necessary